Migraine is a Disabling Neurological Disease that Affects More Than 8.4 Million People in Japan[1],[2]
Aimovig is the First and Only Approved Treatment in Japan to Block the Calcitonin Gene-Related Peptide Receptor (CGRP-R) That Plays an Important Role in Migraine[3]
Aimovig Continues to be the Most Utilized Anti-CGRP Pathway Therapy, With More Than Half a Million Patients Prescribed Worldwide[4]
PR Newswire
THOUSAND OAKS, Calif., June 23, 2021